Physician profile
Elizabeth Ann Evers
NPI 1861412405
$6,824.50
in general payments reported to CMS, 2019-2025
42 companies · $983 in 2025
The $983 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $507 · 2021: $1,062 · 2022: $1,156 · 2023: $1,235 · 2024: $1,213 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,123 · Education: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,123.06 |
| Education | $308.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,812.85 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $1,038.16 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $906.53 | 2019-2025 | |
| Lilly USA, LLC | $525.85 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Pfizer INC. | $418.34 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $232.47 | 2022-2025 | Sotyktu |
| Amgen INC. | $195.02 | 2019-2025 | Krystexxa |
| Exact Sciences Corporation | $171.28 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $135.02 | 2020-2024 | Farxiga, Airsupra |
| Azurity Pharmaceuticals, INC. | $119.08 | 2023-2025 | Edarbi, Horizant, Azmiro |
| Takeda Pharmaceuticals U.S.A., INC. | $113.41 | 2020-2021 | |
| Genzyme Corporation | $105.82 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $100.13 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $99.55 | 2019-2024 | Libtayo |
| Biohaven Pharmaceuticals, INC. | $88.92 | 2021 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.59 | 2023-2024 | Cyltezo |
| Ucb, INC. | $68.25 | 2019-2023 | Bimzelx |
| Biofrontera INC. | $61.36 | 2021-2022 | |
| Novo Nordisk INC | $35.42 | 2023 | Ozempic, Rybelsus |
| Arcutis Biotherapeutics, INC. | $34.76 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $34.42 | 2024-2025 | Aklief, Nemluvio |
| Idorsia Pharmaceuticals US INC | $33.48 | 2023-2025 | Quviviq, Quviviq |
| Merck Sharp & Dohme LLC | $32.14 | 2021-2024 | Capvaxive, Gardasil 9, Gardasil |
| Ethicon US, LLC | $30.66 | 2019-2020 | |
| Clarus Therapeutics INC. | $29.99 | 2021 | |
| Sanofi Pasteur INC. | $25.44 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $24.87 | 2023 | Gvoke Hypopen |
| Incyte Corporation | $24.07 | 2025 | Opzelura |
| Abbott Laboratories | $23.48 | 2024 | Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $22.39 | 2022 | |
| Antares Pharma, INC. | $21.11 | 2024 | Xyosted |
| Halozyme INC | $21.01 | 2023 | |
| Krystal Biotech INC | $20.93 | 2024 | Vyjuvek |
| Sun Pharmaceutical Industries INC. | $20.93 | 2019 | |
| Dermira, INC. | $17.98 | 2019 | |
| Glaxosmithkline, LLC. | $17.80 | 2023 | Shingrix, Arexvy |
| Fresenius Kabi USA, LLC | $17.08 | 2024 | |
| Lnhc, INC | $16.04 | 2025 | Zelsuvmi |
| Kowa Pharmaceuticals America, INC. | $15.53 | 2022 | |
| Ibsa Pharma INC. | $14.39 | 2025 | Flector, Licart, Tirosint |
| Teva Pharmaceuticals USA, INC. | $13.78 | 2025 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Evers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.